Ian is an Associate Professor the University of Leeds and Honorary Consultant Hepatologist at the Liver Unit at St James's University Hospital. His research is focused on the diagnosis and outcomes of patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis, including those relating to hepatocellular carcinoma and liver transplantation.
Stuart J Forbes is Professor of Transplantation and Regenerative Medicine at the University of Edinburgh, Director of the Institute for Regeneration and Repair (IRR), and a Consultant Hepatologist at the Scottish Liver Transplant Unit. <br>After training in medicine at Edinburgh and completing a PhD at Imperial College, he worked as a hepatologist in London before returning to Edinburgh in 2006. His translation research program focuses on liver regeneration, investigating how it fails in liver disease and cancer.
The Wang lab at Mount Sinai NY use single-cell sequencing and imaging based techniques to study liver fibrosis, regeneration, and their crosstalk.
Sharad Wadhwani is a pediatric hepatologist and an Assistant Professor of Pediatrics at the University of California, San Francisco. He research lies at the intersection of pediatric hepatology, population health, and health systems improvement.<br><br>Dr. Wadhwani's research has been funded by AASLD, the Starzl Network for Excellence in Pediatric Transplantation, AGA, American Society of Transplantation, and the NIH.
Dr. Patidar is a Hepatologist and Transplant Hepatologist and Associate Professor of Medicine at Houston Methodist Hospital. He also serves as the Associate Director of Clinical Research for Academic Hepatology at Houston Methodist Hospital. He received his medical degree from West Virginia School of Osteopathic Medicine in 2012. He completed his residency in Internal Medicine and dual fellowships in Gastroenterology and Transplant Hepatology at Virginia Commonwealth University.
Professor O'Brien (UCL and The Royal Free) used to run a laboratory group but was lucky enough to progress an idea from bench to trial and, even though it did not work, found he much preferred doing clinical trials in cirrhosis. He has been very fortunate to deliver the ATTIRE & ASEPTIC UK clinical trials and will shortly begin another, even larger trial, APEACH (The Apixaban to Prevent dEcompensation of eArly liver CirrHosis trial). Hopefully he will be able to do at least one or two more following this daunting task.
Dr. Do is a board-certified hepatologist and Clinical Associate Professor of Medicine at UC Davis Health, where he specializes in general and transplant hepatology, seeing all types of liver diseases and with a passion for steatotic liver disease (metabolic and alcohol-associated liver disease). He provides care to patients with a broad spectrum of general hepatology conditions and is also a member of the UC Davis Liver Transplant Center, offering expertise in pre- and post-transplant management. Dr.
Doug Simonetto is a Transplant Hepatology and Associate Professor of Medicine at Mayo Clinic, Rochester. He serves as the Director of the Gastroenterology and Hepatology Fellowship Program and Co-Director of Data Analytics and Artificial Intelligence Laboratory. His research focuses on portal hypertension and alcohol-associated liver disease.
Nadim Mahmud, MD MS MPH MSCE is an Assistant Professor of Medicine and Epidemiology at the Hospital of the University of Pennsylvania
Dr. Fontana is a Professor of Medicine in the Division of Gastroenterology & Hepatology at the University of Michigan. Over the past 2 decades, Dr Fontana has been involved in prospective registry studies regarding the etiologies and outcomes of acute liver failure and idiosyncratic DILI and clinical trials in viral hepatitis. Dr. Fontana is the Co-PI of the Drug Induced Liver Injury Network Steering Committee and is conducting studies on genetic susceptibility factors and outcomes of DILI.